Background
==========

Diabetic nephropathy (DN) is the leading cause of chronic renal disease and a major cause of cardiovascular mortality. Diabetic nephropathy is associated with cardiovascular disease and increases mortality of diabetic patients \[[@b1-medscimonit-20-1596]\]. Diabetic nephropathy has been categorized into 2 stages: microalbuminuria and macroalbuminuria. Several factors are involved in the pathophysiology of DN, including metabolic and hemodynamic alterations, oxidative stress, activation of the renin-angiotensin system, immunoregulatory cytokines \[[@b2-medscimonit-20-1596],[@b3-medscimonit-20-1596]\] and genetic factors. The 2 main risk factors for diabetic nephropathy are hyperglycemia and arterial hypertension, but the genetic susceptibility in type 1 and type 2 diabetes is of great importance \[[@b4-medscimonit-20-1596]\]. Previous studies have shown that type 2 diabetes (T2D) is a metabolic disorder characterized by hyperglycemia, developing insulin resistance, β-cell dysfunction, and impaired insulin secretion. As the incidence of type 2 diabetes continues to rise world-wide, the personal and social burdens associated with this complication are becoming increasingly serious. A familial study has provided compelling evidence that genetic factors contribute to DN susceptibility in T2D \[[@b5-medscimonit-20-1596]\] as have studies aimed at identifying the causal genes responsible for its development.

The Apolipoprotein E (APO E) gene, located on chromosome 19q13.2, has 3 common alleles -- 2, 3, and 4 -- coding for the 3 main isoforms of the Apo E protein: ɛ2 (Arg→Cys), ɛ3 (parent isoform), and ɛ4 (Arg→Cys). There are 6 common Apo E polymorphisms: Apo ɛ3/3, Apo ɛ4/4, Apo ɛ2/2, Apo ɛ3/2, Apo ɛ4/2, and Apo ɛ4/3 \[[@b6-medscimonit-20-1596]\].

Many studies have investigated gene APO E polymorphism effects on susceptibility to type 2 diabetic nephropathy, and we have summarized the findings of those individual studies in the [Appendix 1](#t3-medscimonit-20-1596){ref-type="table"}. Meta-analysis is a powerful method for quantitatively summarizing results from different studies. One of its advantages is to increase the sample size, which may reduce the probability that random error will result in a false-positive or false-negative association. Therefore, we performed a meta-analysis to quantitatively assess the association of APO E gene polymorphisms with DN.

Material and Methods
====================

Literature search strategy
--------------------------

The Medline, PubMed, Embase, and Web of Science were searched (the last search was updated on June, 10, 2014 using the search terms: 'Diabetic Nephropathy" or "DN", "polymorphism", "APO E" or "Apolipoprotein E". All searched studies were retrieved and their bibliographies were checked for other relevant publications. Review articles and bibliographies of other relevant identified studies were hand-searched in addition to eligible studies. Only published studies with full-text articles were included. When more than one of the same patient populations was included in several publications, only the one with the sample size largest or the most complete study was used in this meta-analysis. A flow diagram of the study selection process is shown in [Figure 1](#f1-medscimonit-20-1596){ref-type="fig"}.

Inclusion and exclusion criteria
--------------------------------

The inclusion and exclusion criteria were determined by discussion. The inclusion criteria were: (1) the study aimed to examine the association between APO E polymorphisms and susceptibility to DN; (2) the design type of the study was a case-control study; (3) the study used diabetic patients without nephropathy or healthy subjects as controls; (4) the study provided the number of DN cases or controls and the frequency of APO E genotypes.

The exclusion criteria were: (1) the study did not fit the diagnosis criteria; (2) the study was conducted on animals; (3) the study was not a case-control study; (4) the study reported useless data; (5) the study focused on type 1 diabetic subjects.

Data extraction
---------------

All of the data were extracted independently by 2 reviewers (Yijin Lin and Jinlin Pan) according to the pre-specified selection criteria. Disagreement was resolved by discussion. The following data were extracted: control type, diabetic duration, study design, first author's name, publication year, and number of cases with normoalbuminuria, microalbuminuria, and macroalbuminuria, and number of healthy controls.

Statistical analysis
--------------------

Allele frequencies at the APO E single-nucleotide polymorphisms (SNPs) from the studies were determined by the allele counting method. Statistical analysis was conducted using Stata 11.0 (StataCorp, College Station, TX) and a *P*-value ≤0.05 was considered to be statistically significant. Dichotomous data are presented as the odds ratio (OR) with a 95% confidence interval (CI). Statistical heterogeneity was measured using the *Q*-statistic (*P*≤0.10 was considered to be representative of statistically significant heterogeneity). We also quantified the effect of heterogeneity using the *I^2^* statistic, which measures the degree of inconsistency in the studies by calculating what percentage of the total variation across studies is due to heterogeneity rather than by chance. A fixed-effects model was used when there was no heterogeneity of the results of the trials; otherwise, the random effects model was used. For dichotomous outcomes, patients with incomplete or missing data and small-sample studies were included in the sensitivity analyses by counting them as treatment failures. To establish the effect of clinical heterogeneity between studies on the conclusions of meta-analyses, subgroup analysis was conducted on the basis of race. Several methods were used to assess the potential for publication bias. Visual inspection of asymmetry in funnel plots was conducted. Begg's rank correlation method and Egger's weighted regression method were also used to statistically assess the publication bias (*P*≤0.05 was considered to be representative of statistically significant publication bias).

Results
=======

Characteristics of studies
--------------------------

This meta-analysis included 16 relevant studies of APO E SNPs, with 1754 cases and 3912 controls. The characteristics of each study are presented in the [Appendix 1](#t3-medscimonit-20-1596){ref-type="table"}.

Quantitative data synthesis
---------------------------

The aim of this study was to use the meta-analysis method to quantitatively summarize the results from the selected individual studies. In comparing DN cases versus diabetic patients without nephropathy, our was aim to evaluate the relationship between APO E polymorphisms on the progress of diabetic patients. The carriers of the APO ɛ2 allele were more likely to have DN than the over-all group, the East Asia group, and the Japan group, but not in the 3 other subgroups (ɛ2 allele *vs.* ɛ3 allele: over-all: pooled *OR*=1.669, 95% *CI*=1.194--2.332, *P*=0.003; East Asia group: pooled *OR*=1.667, 95% *CI*=1.150--2.417, *P*=0.007; Japan group: pooled *OR*=2.352, 95% *CI*=1.228--4.502, *P*=0.010. ɛ2 group *vs.* ɛ3 group: East Asia group: pooled *OR*=1.829, 95% *CI*=1.235--2.711, *P*=0.003; Japan group: pooled *OR*=3.085, 95% *CI*=1.852--5.140, *P*\<0.001) ([Table 1](#t1-medscimonit-20-1596){ref-type="table"} and [Figure 2](#f2-medscimonit-20-1596){ref-type="fig"})

To understand the influence of diabetes duration on the development of diabetes, we divided the included studies into 2 parts by duration of diabetes, comparing the group with \>10 years duration versus the group with duration \<10 years. As [Table 1](#t1-medscimonit-20-1596){ref-type="table"} and [Figure 3](#f3-medscimonit-20-1596){ref-type="fig"} show, the carriers of the APO ɛ2 allele were associated with progression of DN in the duration \> 10 years group, but not in the duration \<10 years group (ɛ2 allele *vs.* ɛ3 allele: pooled *OR*=1.920, 95% *CI*=1.338--2.754, *P*\<0.001; ɛ2 group *vs.* ɛ3 group: pooled *OR*=1.667, 95% *CI*=0.946--2.936, *P*=0.077).

The aim of comparing DN cases and healthy people was to estimate the association of the APO E polymorphisms and susceptibility to DN. The APO ɛ2 polymorphism increased the susceptibility to DN in the Asian population (ɛ2 allele *vs.* ɛ3 allele: pooled *OR*=1.629, 95% *CI*=1.010--2.628, *P*=0.045; ɛ2 group *vs.* ɛ3 group: pooled *OR*=1.531, 95% *CI*=0.964--2.432, *P*=0.071) ([Figure 4](#f4-medscimonit-20-1596){ref-type="fig"}).

To further verify the association of development of DN and APO E polymorphisms, we quantitatively summarized the results of microalbuminuria versus normoalbuminuria and macroalbuminuria versus normoalbuminuria. The meta-analysis results of these 2 comparisons supported the results above -- APO ɛ2 allele polymorphism was associated with the progression of DN ([Table 2](#t2-medscimonit-20-1596){ref-type="table"}).

There were 3 prospective studies among the papers included in this meta-analysis, and the pooled results verified the conclusion of the case-control studies -- the APO ɛ2 allele polymorphism was a risk factor in the development of DN (Progression *vs.* Non-progression: ɛ2 allele *vs.* ɛ3 allele: pooled *RR*=1.636, 95% *CI*=1.093--2.449, *P*=0.017; ɛ2 group *vs.* ɛ3 group pooled *RR*=1.711, 95% *CI*=1.124--2.606, *P*=0.012). We found a significant difference in comparison of 'ɛ2 allele *vs.* ɛ3 allele' group among 'Progression *vs.* Non-progression', but there were no other result supporting this conclusion ([Table 2](#t2-medscimonit-20-1596){ref-type="table"}).

Heterogeneity
-------------

The heterogeneity was calculated among all studies using the Q-statistic (Q\>0.05) and the I^2^ statistic (I=0.0%). Heterogeneity was found in some groups, and the random-effects model was used.

Sensitivity analysis
--------------------

A single study was deleted each time to investigate the influence of the individual dataset on the pooled *OR*s. The corresponding pooled *OR*s were not materially altered (data not shown), indicating that our results are statistically robust.

Publication bias
----------------

Begg's funnel plot and Egger's test were performed to assess the publication bias of the literature. We found no asymmetry of the funnel plot, suggesting that there was no publication bias in our meta-analysis.

Discussion
==========

Diabetic nephropathy (DN) is a major contributor to the high mortality of patients with DM \[[@b23-medscimonit-20-1596]\]. Several acquired risk factors, such as abnormal lipoprotein metabolism, hypertension, and hyperglycemia, have been identified for the development of DN \[[@b24-medscimonit-20-1596]\]. Genetic susceptibility is thought to contribute to the pathogenesis of this complication. Studies of patients with type 2 DM have shown either that the ɛ2 allele is a risk factor for DN or no association between Apo E polymorphism and DN exists in Asian populations. A study conducted in Korean patients with type 2 DM found that the Apo ɛ2 allele was significantly more frequent in the macroalbuminuria group compared with the normoalbuminuria group \[[@b13-medscimonit-20-1596]\]. A Japanese study involving 158 patients with long-term type 2 DM obtained similar results, showing that the ɛ2 allele could increase the risk of DN, and ɛ4 was a protective factor \[[@b9-medscimonit-20-1596]\]. Conversely, there are conflicting results regarding the impact of allele ɛ2 and ɛ4 on the development of DN. The APO ɛ2 allele did not appear to be associated with increased risk of renal impairment in Chinese type 2 diabetic patients \[[@b21-medscimonit-20-1596]\] and a study indicated that the ɛ4 allele of the Apo E polymorphism is one of the prognostic risk factors involved in the development of DN with type 2 diabetes mellitus \[[@b7-medscimonit-20-1596]\].

The results of this study suggest that APO ɛ2 allele is more likely to increase the risk of DN, while APO ɛ4 allele is not associated with the DN development and susceptibility in an East Asia population. Specifically, the OR value of most included studies (3/15) were larger than 1 when the ɛ2 allele and APO ɛ3 was compared ([Figure 2](#f2-medscimonit-20-1596){ref-type="fig"}). This finding indicates that the negative results of those studies might be due to inadequate sample size. In addition to the sample size, another reason for this inconsistency is the duration of diabetes in the DN and non-DN groups. This meta-analysis shows that, in most individual studies in patients with diabetes duration \>10 years group, there is a significant correlation between DN and APO ɛ2, but none of the studies had positive results in subgroups of patients with diabetes duration \<10 years ([Figure 3](#f3-medscimonit-20-1596){ref-type="fig"}). The defective ability of the APO ɛ2 isoform to bind to Apo E receptors may increase the risk of DN.

There are some limitations to this study. Firstly, because only published studies were included in the meta-analysis, publication bias may have occurred, even though it was not found by statistical tests. Secondly, a meta-analysis essentially retains the methodological deficiencies of the included studies. Finally, this meta-analysis is based on unadjusted estimates, while a more precise analysis could be performed if individual data were available.

Conclusions
===========

In conclusion, in spite of several limitations mentioned above, this meta-analysis suggests that APO ɛ2 mutation increased the development of DN, especially in East Asian populations.

Abbreviations: APO E, Apolipoprotein E; DN, Diabetic nephropathy; T2D, Type 2 diabetes; SNPs, single-nucleotide polymorphisms
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###### 

Summary about meta-analysis on APO E polymorphisms in Asian type 2 diabetes patients (with nephropathy *vs.* without nephropathy).

  Comparisons                 Stratification   Subgroups   n                  OR(95% CI)         Homogeneity        Publication Bias                                      
  --------------------------- ---------------- ----------- ------------------ ------------------ ------------------ ------------------ ------- ---------- ------- ------- -------
  ɛ2 allele *vs.* ɛ3 allele   **All**                      **15**             **1.669**          **1.194--2.332**   **0.003**          36.41   0.001      61.5    0.363   0.468
  Region                      **East Asia**    **11**      **1.667**          **1.150--2.417**   **0.007**          28.64              0.001   65.1       0.350   0.330   
  China                       5                1.248       0.790--1.971       0.343              11.03              0.026              63.7    0.462      0.839           
  **Japan**                   **4**            **2.352**   **1.228--4.502**   **0.010**          6.97               0.073              56.9    0.089      0.133           
  Korea                       3                1.988       0.774--5.104       0.153              1.96               0.161              49.0    1.000      --              
  Turkey                      4                1.632       0.650--4.094       0.297              7.44               0.059              59.7    1.000      0.603           
  Diabetes duration           \>10 years       **9**       **1.920**          **1.338--2.754**   **\<0.001**        14.73              0.251   26.8       0.348   0.199   
  \<10 years                  4                0.793       0.480--1.310       0.366              4.10               0.065              45.7    0.734      0.982           
  ɛ4 allele *vs.* ɛ3 allele   All                          15                 1.018              0.854--1.214       0.843              11.44   0.652      0.652   0.310   0.098
  Region                      East Asia        11          1.003              0.830--1.212       0.975              9.25               0.509   0.0        0.161   0.082   
  China                       5                1.097       0.851--1.414       0.475              1.29               0.862              0.862   0.806      0.331           
  Japan                       4                0.917       0.605--1.390       0.682              4.86               0.182              0.182   0.734      0.731           
  Korea                       2                0.698       0.289--1.683       0.423              1.63               0.201              0.201   1.000      --              
  Turkey                      4                1.114       0.696--1.783       0.652              2.02               0.568              0.568   0.734      0.350           
  Diabetes duration           \>10 years       9           0.979              0.750--1.276       0.873              9.80               0.279   18.4       0.251   0.189   
  \<10 years                  4                0.967       0.649--1.442       0.871              1.22               0.749              0.0     0.734      0.800           
  ɛ2 group *vs.* ɛ3 group     All                          16                 1.512              0.987--2.316       0.058              49.72   \< 0.001   69.8    0.760   0.138
  Region                      **East Asia**    **12**      **1.829**          **1.235--2.711**   **0.003**          26.93              0.005   59.1       0.451   0.277   
  China                       5                1.248       0.790--1.971       0.360              8.46               0.076              52.7    1.000      0.861           
  **Japan**                   **5**            **3.085**   **1.852--5.140**   **\<0.001**        4.78               0.311              16.3    1.000      0.713           
  Korea                       2                1.799       0.442--7.319       0.412              3.27               0.071              69.4    1.000      --              
  Turkey                      4                0.704       0.209--2.377       0.572              10.37              0.016              71.1    0.308      0.126           
  Diabetes duration           \>10 years       10          1.667              0.946--2.936       0.077              31.59              0.000   71.5       0.371   0.608   
  \<10 years                  4                0.756       0.475--1.201       0.236              2.33               0.507              0.0     0.734      0.988           
  ɛ4 group *vs.* ɛ3 group     All                          16                 0.834              0.631--1.102       0.202              27.55   0.025      45.6    0.222   0.094
  Region                      East Asia        12          0.878              0.644--1.196       0.409              21.67              0.027   49.2       0.321   0.232   
  China                       5                1.158       0.866--1.549       0.321              3.07               0.547              0.00    0.221      0.159           
  Japan                       5                0.710       0.405--1.245       0.232              10.73              0.030              62.7    0.462      0.566           
  Korea                       2                0.579       0.094--3.552       0.555              4.12               0.042              75.7    1.000      --              
  Turkey                      4                0.659       0.351--1.239       0.195              4.05               0.256              25.9    0.734      0.717           
  Diabetes duration           \>10 years       10          0.723              0.465--1.123       0.149              23.96              0.004   62.4       0.086   0.328   
  \<10 years                  4                0.915       0.586--1.430       0.697              2.54               0.469              0.0     0.592      0.383           

ɛ2 carrier (ɛ2/2, ɛ2/3 genotypes), ɛ3 group (ɛ3/3 genotype) and ɛ4 group (ɛ3/4, ɛ4/4 genotype).

###### 

Summary about meta-analysis on APOE polymorphisms in Asian type 2 diabetes patients with nephropathy (DN *vs.* with nephropathy; microalbuminuria *vs.* normoalbuminuria; macroalbuminuria *vs.* normoalbuminuria; progress *vs.* non-progress).

  Comparisons                                           Stratification                 n                OR/RR(95% CI)      Homogeneity        Publication Bias                                    
  ----------------------------------------------------- ------------------------------ ---------------- ------------------ ------------------ ------------------ ------- -------- ------- ------- -------
  ɛ2 allele *vs.* ɛ3 allele                             **DN** ***vs.*** **healthy**   **7**            **1.629**          **1.010--2.628**   **0.045**          12.88   0.045    53.4    0.230   0.255
  **Microalbuminuria** ***vs.*** **normoalbuminuria**   **4**                          **1.619**        **1.087--2.414**   **0.018**          1.13               0.770   0.0      1.000   0.870   
  Macroalbuminuria *vs.* normoalbuminuria               3                              1.808            0.980--3.337       0.058              4.42               0.110   54.7     1.000   0.469   
  **Progress** ***vs.*** **non-progress**               **3**                          ***RR*=1.636**   **1.093--2.449**   **0.017**          4.18               0.124   52.2     0.602   0.527   
  ɛ4 allele *vs.* ɛ3 allele                             DN vs. healthy                 7                0.929              0.566--1.522       0.769              20.38   0.002    70.6    1.000   0.658
  Microalbuminuria *vs.* normoalbuminuria               4                              0.792            0.541--1.160       0.231              2.75               0.431   0.0      0.308   0.553   
  Macroalbuminuria *vs.* normoalbuminuria               3                              0.992            0.601--1.639       0.976              1.01               0.605   0.0      1.000   0.208   
  **Progress** ***vs.*** **non-progress**               **3**                          ***RR*=1.597**   **1.025--2.486**   **0.038**          2.21               0.331   9.5      1.000   0.132   
  ɛ2 group *vs.* ɛ3 group                               DN *vs.* healthy               7                1.531              0.964--2.432       0.071              9.76    0.135    38.6    0.548   0.352
  Microalbuminuria *vs.* normoalbuminuria               4                              1.382            0.874--2.187       0.167              1.13               0.771   0.0      0.806   0.291   
  **Macroalbuminuria** ***vs.*** **normoalbuminuria**   **3**                          **2.081**        **1.080--4.010**   **0.028**          2.81               0.245   28.8     0.734   0.649   
  **Progress** ***vs.*** **non-progress**               **3**                          ***RR*=1.711**   **1.124--2.606**   **0.012**          3.08               0.215   35.0     1.000   0.786   
  ɛ4 group *vs.* ɛ3 group                               DN *vs.* healthy               7                0.927              0.486--1.769       0.819              26.81   \<0.01   77.6    1.000   0.831
  Microalbuminuria *vs.* normoalbuminuria               4                              0.687            0.443--1.065       0.093              3.96               0.266   24.3     0.806   0.436   
  Macroalbuminuria *vs.* normoalbuminuria               3                              1.153            0.663--2.003       0.614              0.62               0.734   0.0      0.308   0.278   
  Progress *vs.* non-progress                           3                              RR=1.533         0.952--2.468       0.087              2.15               0.342   6.8      0.296   0.127   

ɛ2 carrier (ɛ2/2, ɛ2/3 genotypes), ɛ3 group (ɛ3/3 genotype) and ɛ4 group (ɛ3/4, ɛ4/4 genotype). The progressors on DN were defined as the subjects who shifted to a higher stage of DN from that at the baseline.

###### 

Findings of the studies included in this meta-analysis.

  Studies                                             Year   Country   Number   Conclusion         
  --------------------------------------------------- ------ --------- -------- ------------ ----- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Necip I'lhan \[[@b7-medscimonit-20-1596]\]          2007   Turkey    37       71           46    In conclusion, the present prospective study indicates that thee4 allele of the Apo E polymorphism is one of the prognostic risk factors involved in the development of DN with type 2 diabetes mellitus
  Shin-ichi Araki \[[@b8-medscimonit-20-1596]\]       2003   Japan     31       398          --    Our follow-up study indicates that the 2 allele of the APO E polymorphism is a prognostic risk factor for both the onset and the progression of diabetic nephropathy in Japanese type 2 diabetes
  Masaaki Eto \[[@b9-medscimonit-20-1596]\]           2001   Japan     99       59           --    Apo E2 is a positive factor and apo E4 is a negative factor for diabetic nephropathy. Apo E2 TG-rich lipoproteins, including remnant lipoproteins, affected HMCs. Remnant lipoproteins may have an important role in the progression of diabetic nephropathy
  Kai-Jen Tien \[[@b10-medscimonit-20-1596]\]         2011   China     136      382          576   Our study suggests the apo E4 carrier might serve as a predictor of DN progression in Taiwan
  Kazutoshi Horita \[[@b11-medscimonit-20-1596]\]     1994   Japan     57       398          --    It is concluded that apo E2 is associated with renal insuffkiency in NIDDM and that apo E2 may be a factor that aggravates lipid abnormalities in NIDDM with renal failure
  Mi-Kwang Kwon \[[@b12-medscimonit-20-1596]\]        2007   Korea     36       58           --    These data suggest that E4 carrier might be associated with the protection for the development of diabetic nephropathy in type 2 diabetic patients without respect to dyslipidemia
  Sung kyu Ha \[[@b13-medscimonit-20-1596]\]          1999   Korea     74       93           --    Apo E2 allele and E2 carrier frequencies were significantly higher in macroalbuminuria group. These results suggest that E2 allele may be associated with the development of clinical albuminuria in Korean Patients with NIDDM
  Ng MCY \[[@b14-medscimonit-20-1596]\]               2006   China     366      386          200   Our findings suggest the importance of interactions among lipid genes in modulating the risk of DN
  Kadriye Altok Reis \[[@b15-medscimonit-20-1596]\]   2010   Turkey    106      110          --    Our study has shown that AGT M235T TT genotype and APO E ɛ2/3 genotype may be linked to a risk for DN among Turkish population
  Limei Liu \[[@b16-medscimonit-20-1596]\]            2003   China     218      80           81    These results suggest that the HSPG T allele is a risk factor for the development of severe diabetic nephropathy in type 2 diabetic patients, and that the Apo E E2 allele is a risk factor for the occurrence of type 2 diabetes mellitus in Chinese general population. In addition, we find that co-inheritance of T/E2 confers a higher risk of type 2 diabetes mellitus progression to diabetic nephropathy in Chinese
  Ming-chia Hsieh \[[@b17-medscimonit-20-1596]\]      2002   China     215      100          150   These findings imply that apo E polymorphism is apparently related to the development of DN in type 2 diabetes in Taiwan
  Eto M. \[[@b18-medscimonit-20-1596]\]               1995   Japan     146      135          --    It is concluded that is a possibility that the ɛ2 allele is associated with nephropathy in NINNM
  Hideki Kimura \[[@b19-medscimonit-20-1596]\]        1997   Japan     81       96           251   Results indicate that apolipoprotein E polymorphism is associated with the progression of diabetic nephropathy. Presence of the apolipoprotein E4 allele is a protective factor, and other alleles are risk factors
  M. Erdogan \[[@b20-medscimonit-20-1596]\]           2009   Turkey    46       56           35    We conclude that the Apo E gene polymorphism is not associated with the development of diabetic nephropathy in Turkish Type 2 diabetic patients. Lack of association between Apo E gene polymorphism and Type 2 diabetic nephropathy might be due to ethnic differences
  Shuk-Woon Ma \[[@b21-medscimonit-20-1596]\]         2008   China     112      169          --    The APOE ɛ2 allele does not seem to be associated with increased risk of renal impairment in Chinese type 2 diabetic patients. Plasma lipid-standardized α-tocopherol may play a role in determining risk of renal dysfunction in type 2 diabetes
  Akarsu E. \[[@b22-medscimonit-20-1596]\]            2001   Turkey    24       22           --    As a result, we concluded that the ɛ2 allele of apo E may play a role in the mechanism of nephropathy in type 2 diabetes mellitus
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